Journal
GEBURTSHILFE UND FRAUENHEILKUNDE
Volume 78, Issue 10, Pages 972-976Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/a-0717-5411
Keywords
ovarian cancer; low-grade serous; rare tumour
Categories
Funding
- Amgen
- Roche
Ask authors/readers for more resources
In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available